Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Assembly Biosciences Inc ASMB

Healthcare Biotechnology
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle... see more

Recent & Breaking News (NDAQ:ASMB)

Data for Assembly Biosciences' First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019

GlobeNewswire November 11, 2019

Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire November 7, 2019

Assembly Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights

GlobeNewswire November 7, 2019

Assembly Biosciences Appoints Luisa Stamm, MD, PhD, as Chief Medical Officer

GlobeNewswire November 7, 2019

Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire October 28, 2019

Assembly Biosciences Appoints Thomas J. Russo as Chief Financial Officer

GlobeNewswire October 28, 2019

Safety and Antiviral Activity of Assembly Biosciences' First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASLD

GlobeNewswire October 16, 2019

Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire August 9, 2019

Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer

GlobeNewswire August 7, 2019

Assembly Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights

GlobeNewswire August 5, 2019

Assembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis

GlobeNewswire June 27, 2019

Assembly Biosciences Announces Participation in the Microbiome Movement Drug Development Summit

GlobeNewswire June 25, 2019

Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China

GlobeNewswire June 21, 2019

Assembly Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights

GlobeNewswire May 9, 2019

Assembly Biosciences Announces Changes to Senior Leadership Team

GlobeNewswire May 2, 2019

Development Veteran Steven J. Knox Joins Assembly Biosciences as Senior Vice President, Clinical Development

GlobeNewswire April 22, 2019

Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019

GlobeNewswire April 13, 2019

Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019

GlobeNewswire April 11, 2019

Assembly Biosciences Announces Multiple Abstracts Highlighting HBV Core Inhibitor Portfolio Accepted for Oral and Poster Presentations at EASL 2019

GlobeNewswire March 27, 2019

Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit

GlobeNewswire March 13, 2019